Barry Zeffren, MD
Allergy & Immunology · Glen Carbon, ILNPI 1205908639
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,300 of the $17,769 with a category attached, or 80.5%. GSK accounts for 84.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $5,874 and has fallen 93.9% since, to $357 in 2025.
Across 211 payments — averaging $84.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$15K
- AstraZeneca$1K
- Sanofi$357
- Novartis$164
- Alk-abello, Inc$156
- Takeda Pharmaceuticals U.S.A., Inc.$115
- plus $742 from 14 others
What the payments were for
- Speaking & faculty fees$14,30080%
- Food & beverage$3,45419%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 75 | $15,028 |
| AstraZeneca | 45 | $1,208 |
| Sanofi | 22 | $357 |
| Novartis | 11 | $164 |
| Alk-abello, Inc | 6 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $115 |
| Grifols USA, LLC | 6 | $111 |
| Optinose US, Inc. | 7 | $107 |
| Genentech USA, Inc. | 6 | $92 |
| Kaleo, Inc. | 5 | $85 |
| Regeneron Healthcare Solutions, Inc. | 4 | $68 |
| Pfizer | 4 | $59 |
| CSL Behring | 3 | $48 |
| Biocryst US Sales Co., LLC | 3 | $46 |
| Pharming Healthcare, Inc. | 2 | $32 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Octapharma USA, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $15 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,769 in reported general payments places this provider in the 80th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 43 | $189,323 |
| XolairOmalizumab | 57 | $167,561 |
| HyqviaIgg/Hyaluronidase,recombinant | 17 | $154,138 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $100,404 |
| FasenraBenralizumab | 16 | $95,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $79,757 |
| Breo ElliptaFluticasone/Vilanterol | 116 | $58,850 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $12,576 |
| Spiriva HandihalerTiotropium Bromide | 25 | $12,541 |
| Arnuity ElliptaFluticasone Furoate | 35 | $10,878 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $10,148 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $7,742 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $5,677 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $5,265 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $115 | $154,13817 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $15,028 | $149,485252 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $1,208 | $118,47178 claims |
| Grifols USA, LLCGamunex-C | $111 | $100,40424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Glen Carbon
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
- Zachary RubinElmhurst$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.